The lignan niranthin poisons Leishmania donovani topoisomerase IB and favours a Th1 immune response in mice
Open Access
- 2 October 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in EMBO Molecular Medicine
- Vol. 4 (10), 1126-1143
- https://doi.org/10.1002/emmm.201201316
Abstract
Niranthin, a lignan isolated from the aerial parts of the plant Phyllanthus amarus, exhibits a wide spectrum of pharmacological activities. In the present study, we have shown for the first time that niranthin is a potent anti‐leishmanial agent. The compound induces topoisomerase I‐mediated DNA–protein adduct formation inside Leishmania cells and triggers apoptosis by activation of cellular nucleases. We also show that niranthin inhibits the relaxation activity of heterodimeric type IB topoisomerase of L. donovani and acts as a non‐competitive inhibitor interacting with both subunits of the enzyme. Niranthin interacts with DNA–protein binary complexes and thus stabilizes the ‘cleavable complex’ formation and subsequently inhibits the religation of cleaved strand. The compound inhibits the proliferation of Leishmania amastigotes in infected cultured murine macrophages with limited cytotoxicity to the host cells and is effective against antimony‐resistant Leishmania parasites by modulating upregulated P‐glycoprotein on host macrophages. Importantly, besides its in vitro efficacy, niranthin treatment leads to a switch from a Th2‐ to a Th1‐type immune response in infected BALB/c mice. The immune response causes production of nitric oxide, which results in almost complete clearance of the liver and splenic parasite burden after intraperitoneal or intramuscular administration of the drug. These findings can be exploited to develop niranthin as a new drug candidate against drug‐resistant leishmaniasis.This publication has 63 references indexed in Scilit:
- Novel Betulin Derivatives as Antileishmanial Agents with Mode of Action Targeting Type IB DNA TopoisomeraseMolecular Pharmacology, 2011
- Leishmaniasis: complexity at the host–pathogen interfaceNature Reviews Microbiology, 2011
- Phase IV Trial of Miltefosine in Adults and Children for Treatment of Visceral Leishmaniasis (Kala-Azar) in BangladeshThe American Journal of Tropical Medicine and Hygiene, 2011
- Lipsosomal Amphotericin B for Treatment of Cutaneous LeishmaniasisThe American Journal of Tropical Medicine and Hygiene, 2010
- Inhibition of ABC Transporters Abolishes Antimony Resistance inLeishmaniaInfectionAntimicrobial Agents and Chemotherapy, 2008
- An insight into the mechanism of inhibition of unusual bi-subunit topoisomerase I fromLeishmania donovaniby 3,3′-di-indolylmethane, a novel DNA topoisomerase I poison with a strong binding affinity to the enzymeBiochemical Journal, 2007
- Camptothecin and Podophyllotoxin DerivativesDrug Safety, 2006
- Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovaniCell Death & Differentiation, 2004
- Reconstitution and functional characterization of the unusual bi‐subunit type I DNA topoisomerase from Leishmania donovaniFEBS Letters, 2004
- Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis.JCI Insight, 1985